CytoSorbents Corp., a Monmouth Junction-based innovator in the healthcare equipment and supplies sector, has formally notified the Securities and Exchange Commission (SEC) that it will miss the mandatory filing deadline for its quarterly report for the period ending September 30, 2026.

The company has indicated that the delay is necessitated by the requirement for additional time to resolve specific accounting matters pertaining to foreign-currency gains and losses. According to the disclosure, management anticipates that the filing will be completed within five days following the original due date. Crucially, the company has maintained that no other material changes or significant shifts in operating results are expected to impact the forthcoming financial statements.

This administrative delay comes at a pivotal moment for the Nasdaq-listed firm. CytoSorbents continues to focus its strategic efforts on the research, development, and commercialization of its proprietary blood purification technology. The company’s core mission remains the integration of these medical devices into various clinical applications to address complex health complications arising from blood toxicity, aiming to revolutionize the treatment of both acute and chronic conditions.

Despite the current accounting adjustments, the company’s market position remains a subject of intense scrutiny within the healthcare technology landscape. With a market capitalization of approximately $14.5 million and a recent closing price of $5.565, the firm is navigating a period of significant volatility, having seen its stock trade between a 52-week low of $2.84 and a high of $17.00.

As the company works to finalize its financial reporting, the focus for stakeholders remains on the successful scaling of its blood purification solutions and the long-term commercial viability of its technological pipeline.